A novel treatment strategy for therapy refractory ventricular arrhythmias in the setting of arrhythmogenic right ventricular dysplasia

16Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Abstract

Arrhythmogenic right ventricular dysplasia (ARVD) is a major cause of ventricular tachycardia and cardiac arrest in young adults. The ideal management of this genetic disorder is individual. The treatment options are antiarrhythmic drug therapy, transcatheter radiofrequency catheter ablation, implantable cardioverter defibrillator therapy, and surgical treatment [Kies P, Bootsma M, Bax J, Schalij MJ, van der Wall EE. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: screening, diagnosis, and treatment. Heart Rhythm 2006;3:225-34; Verma A, Kilicaslan F, Schweikert RA et al. Short- and long-term success of substrate-based mapping and ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia. Circulation 2005;111:3209-16]. In the following, we describe a unique case of a young patient, presenting with therapy refractory ventricular arrhythmias in the setting of ARVD, who following failed catheter ablations, has been successfully treated with beating heart cryoablation. © The European Society of Cardiology 2007. All rights reserved.

Cite

CITATION STYLE

APA

Bakir, I., Brugada, P., Sarkozy, A., Vandepitte, C., & Wellens, F. (2007). A novel treatment strategy for therapy refractory ventricular arrhythmias in the setting of arrhythmogenic right ventricular dysplasia. Europace, 9(5), 267–269. https://doi.org/10.1093/europace/eum029

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free